Ionis Pharmaceuticals is trading 4.38% higher at $46.45 on September 28, 2026; available reporting does not identify a cause. - Investor relations lists positive interim Phase 3 IgAN data, released September 22, as its latest news. - Analyst rating reiterations and positive late-stage trial news appeared September 24–25, but do not establish a direct cause. - The broader market is lower amid renewed Middle East tensions, rising oil prices and Treasury yields; this does not directly explain the gain. No volume figure was provided.